Celgene Announces Launch of “Innovation Impact” Awards to Recognize Excellence in Creative Patient, Caregiver or Healthcare Provider Programs
Deadline for Applications is July 31st, 2013; Submissions Accepted Online Only at www.innovationimpact.com
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG), announced today the initiation of the Innovation Impact Awards to recognize effective, innovative and successful initiatives in one of two therapeutic areas: hematology or oncology. The program aims to recognize the achievements of US-based not-for-profit organizations addressing the needs of patients, caregivers and healthcare providers in todays challenging healthcare environment.
The Innovation Impact Awards represent an opportunity to highlight initiatives that have had a demonstrable impact on the lives of patients, families, caregivers and/or the medical professionals who provide treatment and care, said Joel Beetsch, Vice President, Patient Advocacy at Celgene. One of Celgenes goals with the Innovation Impact Awards is to ensure that the selected programs have an opportunity to flourish and evolve. Thats why were asking participants to share plans on how they plan to build on their success and take their program to the next level.
Applications are now being accepted. Submissions must demonstrate inspired innovation, a validated need, proven impact, measurable results and show how it will build on its current success. An independent judging panel comprised of innovation, healthcare and advocacy experts will select two winners; one in oncology and one in hematology.
Winners will be announced by October 15, 2013 and each winner will receive a $100,000 monetary award. Award winners will be invited to participate in an exclusive day-long Innovation Experience that will feature a workshop led by an innovation expert.
Applications are restricted to patient and professional organizations and associations with an interest in hematology or oncology. Organizations must be classified as a not-for-profit and headquartered in the United States. Consideration for awards will not be given to individuals, medical facilities or research institutions. Nor will applications be accepted for pre-clinical, clinical or translational research programs. Each organization may submit only one entry.
For more information visit http://www.innovationimpact.com to learn more about our Awards program, including: the evaluation criteria, experts serving on our judging panel, frequently asked questions, and terms and conditions for the Awards.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
For more information, please visit the Company's website at www.celgene.com.
Source: Celgene CorporationCopyright Business Wire 2013